Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors
Published: December 8, 2025 Dyne Therapeutics (NASDAQ: DYN) is back on biotech investors’ radar after releasing highly anticipated topline data from its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy (DMD), sending the stock sharply higher on Monday. By mid‑afternoon